Bio-gene Technology Share Price and Company Fundamentals



Price
$0.19
Change
0.010 (5.556%)
52 week
0.12 - 0.22

Last traded: Yesterday at 5:28 AM

Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

5.94

Dividend yield

Beta

0.17

Market cap

$29.19M

Enterprise value

$24.19M

Company profile

Primary activitiesDevelopment and commercialisation of insecticide products
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.bio-gene.com.au
Mailing address456 Lonsdale Street Level 11 Melbourne VIC 3000 Australia
Phone / Fax61 3 9068 1062 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Bio-gene Technology does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Bio-gene Technology.

NameTitleAgeTotal Pay
Mr. Richard Jagger B.Sc., BSC (HONS), M.INTL.BUS, GAICDMD, CEO & Director325.39k
Mr. Roger McPherson C.P.A., CPA, B.Bus, GAICDCFO & Company Sec.149.67k
Mr. Peter Donald May AFAIM, M.B.A., MBA, AFA1M, GAICDExec. Director of R&D and Exec. Director228.81k

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-2,836.81%

Return on assets

-28.27%

Return on equity

-49.17%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Bio-gene Technology is 29.19M and its enterprise value is 24.19M. The enterprise value to revenue ratio of BGT is 292.19.

The BGT's stocks Beta value is 0.17 making it 83% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Bio-gene Technology (BGT)

Bio-gene Technology (ASX:BGT) Frequently Asked Questions

1. What is Bio-gene Technology's Stock Symbol?

Bio-gene Technology trades on ASX under the ticker symbol "BGT".

2. What is Bio-gene Technology's stock price today?

One share of BGT stock can currently be purchased for approximately $0.19.

3. How can I contact Bio-gene Technology?

Bio-gene Technology's mailing address is 456 Lonsdale Street Level 11 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9068 1062.

4. What is Bio-gene Technology's official website?

The official website of Bio-gene Technology is http://www.bio-gene.com.au.

5. Which share registry manages Bio-gene Technology's stock?

Bio-gene Technology's stock is managed by AUTOMIC REGISTRY SERVICES.